DSM Biologics To Acquire Rhobust Technology From Upfront Chromatography
As a result of the acquisition, DSM Biologics will gain all rights for the commercialisation of the Rhobust technology in various fields, including the pharma industry. The Rhobust
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.